Pfizer Shares Rise on RBC Upgrade and Regulatory Updates

Pfizer shares climbed roughly 3.2% on June 11, 2026, after two catalysts converged: RBC Capital Markets lifted its rating on PFE to Sector Perform from Underperform, and the FDA expanded the U.S. label for HYMPAVZI (marstacimab) to cover additional hemophilia patient populations. The analyst move, attributed to RBC's Trung Huynh, came with a $25 price target and cited a valuation reset after the stock pulled back roughly 11% from its 2026 highs, bringing PFE to about 9x one-year forward earnings.

The HYMPAVZI label expansion, announced June 8, 2026, broadens the drug's approved U.S. indication to include hemophilia A or B patients aged 6 and older, with or without inhibitors. Previously limited to patients 12 and older, the updated label positions HYMPAVZI as the first subcutaneous non-factor therapy approved for children aged 6 to 11 with hemophilia B. The combined regulatory win and analyst upgrade gave investors a clearer near-term growth narrative for Pfizer's rare disease franchise.

RBC's upgrade note also flagged Pfizer's 7% dividend yield as a downside buffer and pointed to two additional pipeline readouts on the horizon: sigvotatug vedotin in second-line lung cancer expected mid-2026 and the obesity candidate mevro in the second half of 2026. Separately, analysts have noted a German drug pricing negotiation as a near-term risk that could weigh on European revenue for certain products, though that overhang did not prevent today's move higher.

Investors will likely monitor how quickly HYMPAVZI penetrates the pediatric hemophilia segment and whether upcoming pipeline data from sigvotatug vedotin and mevro can add further momentum. Pfizer's ability to sustain the stock re-rating may also depend on broader macro conditions and whether RBC's more balanced risk-reward view draws other analysts to revisit their ratings.